Better diabetic retinopathy outcomes seen with monthly ranibizumab

09/6/2013 | Medscape (free registration)

Data on diabetic retinopathy patients showed those who received monthly ranibizumab treatment were more likely than those who received sham injections to attain improvements in vision and disease severity at three years. Researchers also found patients in the ranibizumab arm were three times less likely to develop proliferative diabetic retinopathy than those in the control group. The findings were presented at the American Society of Retina Specialists meeting.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC